Pegylated granulocyte colony-stimulating factor primary prophylaxis versus no prophylaxis in patients with unresectable pancreatic cancer treated with modified-FOLFIRINOX: a randomized, open-label, multicenter, phase 2 trial.

Importantly, prophylactic peg-GCSF use was associated with improved patient-reported quality of life without an increase in bone pain and showed a numerical trend toward improved survival.

also in 1,012 other papers

Moreover, peg-GCSF prophylaxis was an independent significant factor for better PFS (HR 0.60, P = 0.049) and showed a trend toward better OS in multivariate analyses.

also in 53,322 other papers